Market Cap 260.64B
Revenue (ttm) 42.11B
Net Income (ttm) 14.64B
EPS (ttm) N/A
PE Ratio 19.60
Forward PE 16.97
Profit Margin 34.78%
Debt to Equity Ratio 0.72
Volume 32,220,600
Avg Vol 8,595,936
Day's Range N/A - N/A
Shares Out 4.49B
Stochastic %K 8%
Beta 0.61
Analysts Sell
Price Target $108.80

Latest News on NVO

Selling America, Buying Europe - My Picks

Apr 20, 2025, 9:15 AM EDT - 20 hours ago

Selling America, Buying Europe - My Picks

ASML AZN


Novo Nordisk: A Price Too Low To Ignore

Apr 18, 2025, 10:52 AM EDT - 2 days ago

Novo Nordisk: A Price Too Low To Ignore


Rebecca Walser: Hold NVDA, Buy NVO & LRCX, Caution MCD

Apr 17, 2025, 8:55 AM EDT - 3 days ago

Rebecca Walser: Hold NVDA, Buy NVO & LRCX, Caution MCD

MCD NVDA


Novo Nordisk's head of commercial strategy steps down

Apr 3, 2025, 2:35 AM EDT - 18 days ago

Novo Nordisk's head of commercial strategy steps down


Novo Nordisk announces changes in Executive Management

Apr 3, 2025, 2:00 AM EDT - 18 days ago

Novo Nordisk announces changes in Executive Management


Novo Nordisk: Finally A Buying Opportunity

Mar 30, 2025, 10:37 AM EDT - 21 days ago

Novo Nordisk: Finally A Buying Opportunity


Novo Nordisk says compounded drugs are hurting Wegovy sales

Mar 28, 2025, 9:41 AM EDT - 23 days ago

Novo Nordisk says compounded drugs are hurting Wegovy sales


Resolutions from the Annual General Meeting of Novo Nordisk A/S

Mar 27, 2025, 11:17 AM EDT - 24 days ago

Resolutions from the Annual General Meeting of Novo Nordisk A/S


Buy Low, Never Sell - 2 Elite Dividend Stocks Built To Last

Mar 26, 2025, 7:30 AM EDT - 25 days ago

Buy Low, Never Sell - 2 Elite Dividend Stocks Built To Last

ENB